Faeth Therapeutics, Inc.

Name: Faeth Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

FTHNasdaqCIK 1829802HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$18.4m, Q2 FY2026

Net income−$16.0m, Q2 FY2026

Faeth Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Research and development	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Operating income	$m	(7.7)	(8.1)	(8.7)	(7.8)	(7.8)	(8.3)	(7.3)	(5.2)	(4.9)	(5.0)	(171)	(18.4)
Interest expense	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	not reported	not reported
Income tax	$m	0.0	not reported	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	$m	(7.1)	(7.4)	(8.0)	(7.1)	(7.3)	(7.8)	(6.9)	(4.9)	(4.6)	(4.7)	(170)	(16.0)
Diluted EPS	$ per share	(0.28)	not reported	(0.32)	(5.69)	(5.77)	not reported	(5.45)	(3.91)	(3.62)	not reported	(131.45)	(2.84)
Basic EPS	$ per share	(0.28)	not reported	(0.32)	(5.69)	(5.77)	not reported	(5.45)	(3.91)	(3.62)	not reported	(131.45)	(2.84)

Balance sheet

Cash and equivalents$26.9m, Q2 FY2026

Shareholders' equity$173.0m, Q2 FY2026

Faeth Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	11.3	13.0	11.0	11.9	19.1	10.0	9.9	12.6	10.6	8.7	152	26.9
Current assets	$m	73.8	67.3	60.2	53.9	48.1	41.9	35.7	29.6	25.8	21.5	204	189
Total assets	$m	81.7	74.4	66.7	59.8	53.3	45.4	38.3	31.8	27.6	22.9	205	189
Current liabilities	$m	6.2	5.6	5.0	4.9	5.4	5.4	5.2	3.9	4.4	4.3	14.2	9.6
Total liabilities	$m	10.7	9.5	8.2	7.6	7.5	7.0	6.3	4.5	4.6	4.3	14.2	9.6
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	71.0	64.9	58.5	52.2	45.8	38.4	32.0	27.3	23.0	18.6	(137)	173

Cash flow

Operating cash flow−$15.7m, Q2 FY2026

Capital expenditure$0, Q2 FY2026

Share repurchases$252.0k, Q4 FY2023

Faeth Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(4.7)	(6.2)	(7.6)	(5.8)	(5.5)	(5.8)	(7.1)	(5.9)	(3.6)	(3.9)	(10.7)	(15.7)
Capital expenditure	$m	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Share repurchases	$m	2.3	0.3	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)5.64m, Q2 FY2026

Faeth Therapeutics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	30.7	30.9	30.5	25.5	25.0	1.3	1.3	1.3	1.3	1.3	1.3	5.6

Shares outstanding: 25.84m at Jul 30, 2026, from the cover of the 10-Q filed Aug 4, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.